Adaptimmune Therapeutics has entered into a definitive agreement for the sale of Tecelra, lete-cel, afami-cel, and uza-cel cell therapies to US WorldMeds.   The purchase price is $55 million in cash to be paid upon consummation of the sale, with up to $30 million in potential future payments upon achievement of certain milestones.  Adrian Rawcliffe, Adaptimmune's […]